BEVERLY: A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with EGFR mutated advanced non squamous non small cell lung cancer

Non-squamous Non-small Cell Lung Cancer

To test whether the combination of bevacizumab and erlotinib can prolong investigator assessed (IA-PFS) and blinded independent centrally-reviewed progression-free survival (BICR-PFS) as compared with erlotinib alone as first-line treatment in patients with NSCLC with activating mutation of EGFR. Note: CT (or other pertinent) scans performed at baseline and during follow-up will be collected and reviewed by an independent central panel of radiologists who will be blinded to the assigned tr

• To compare the two arms in terms of o overall survival o quality of life (EORTC C30 + LC13) o centrally reviewed objective response rate (RECIST v.1.1) o investigator assessed objective response rate (RECIST v.1.1) o adverse events (CTCAE 4.03 version) • To test whether an interaction exists between treatment arms and type of EGFR mutation (exon 19del vs exon 21 L858R vs other) • To explore other possible predictive factors and their interaction with treatment arms • To explore pro

No related papers found yet.

Italy